Isimertininb (Tagrisso) for glioblastoma – pro
NCCN on p. GLIO-12. 2026 for recurrent glioblastoma lists recommendations for recurrent glioblastoma, but also says: ” The treatment recommendations on this page are general high-grade glioma options. Tumor MGMT status and next-generation sequencing (NGS) should be performed to possibly expand therapeutic options.” THis si areasonable recommendation for this drug, based on early studies cited below.
Cardona AF, Jaramillo-Velásquez D, Ruiz-Patiño A, Polo C, Jiménez E, Hakim F, Gómez D, Ramón JF, Cifuentes H, Mejía JA, Salguero F, Ordoñez C, Muñoz Á, Bermúdez S, Useche N, Pineda D, Ricaurte L, Zatarain-Barrón ZL, Rodríguez J, Avila J, Rojas L, Jaller E, Sotelo C, Garcia-Robledo JE, Santoyo N, Rolfo C, Rosell R, Arrieta O. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J Neurooncol. 2021 Sep;154(3):353-364. doi: 10.1007/s11060-021-03834-3. Epub 2021 Sep 9. PMID: 34498213.
Hu, L., Shi, J., Shen, D. et al. Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells. Cell Death Discov. 9, 333 (2023). https://doi.org/10.1038/s41420-023-01632-6
Joshua Nahm ,et al, Jay-Jiguang Zhu et al, BIOM-44. IMPROVED OVERALL SURVIVAL OF RECURRENT GLIOBLASTOMA (GBM) PATIENTS WITH EGFR AMPLIFICATION AND EGFR VIII MUTATIONS TREATED WITH OSIMERTINIB: A RETROSPECTIVE REVIEWNeuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v14, https://doi.org/10.1093/neuonc/noad179.0055
10 Novem